Capital Advisors Ltd’s Takeda Pharmaceutical TAK Stock Holding History

Capital Advisors Ltd’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-76	Closed	-$1K	–	1543
2022 Q4	$1K	Hold	76	–	–	﹤0.01%	1093
2022 Q3	$1K	Hold	76	–	–	﹤0.01%	1124
2022 Q2	$1K	Hold	76	–	–	﹤0.01%	892
2022 Q1	$1K	Hold	76	–	–	﹤0.01%	804
2021 Q4	$1K	Hold	76	–	–	﹤0.01%	746
2021 Q3	$1K	Hold	76	–	–	﹤0.01%	494
2021 Q2	$1K	Hold	76	–	–	﹤0.01%	471
2021 Q1	$1K	Hold	76	–	–	﹤0.01%	470
2020 Q4	$1K	Hold	76	–	–	﹤0.01%	441
2020 Q3	$1K	Hold	76	–	–	﹤0.01%	442
2020 Q2	$1K	Sell	76 -60	-44%	-$1.08K	﹤0.01%	439
2020 Q1	$7K	Buy	136 +60	+79%	+$1.09K	﹤0.01%	395
2019 Q4	$1K	Hold	76	–	–	﹤0.01%	404
2019 Q3	$1K	Hold	76	–	–	﹤0.01%	399
2019 Q2	$1K	Hold	76	–	–	﹤0.01%	431
2019 Q1	$2K	Buy	+76	New	+$1.53K	﹤0.01%	420

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Capital Advisors Ltd's TAK Position: Q1 2023 in Review

Capital Advisors Ltd sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 76 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in TAK in Q1 2019 and held it in 16 quarters. The position peaked at $7K in Q1 2020. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

Capital Advisors Ltd reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Capital Advisors Ltd sold 76 Takeda Pharmaceutical shares in Q1 2023, an estimated $1K.
Capital Advisors Ltd first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 16 quarters.
Capital Advisors Ltd's Takeda Pharmaceutical position peaked at $7K in Q1 2020.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.